Estimated pneumococcal disease burden in children due to serotypes covered by different pneumococcal conjugate vaccines in five Latin American countries - Summary - MDSpire
Advertisement
Estimated pneumococcal disease burden in children due to serotypes covered by different pneumococcal conjugate vaccines in five Latin American countries
To estimate the clinical, economic, and societal burden of pneumococcal disease attributable to serotypes contained in PCV10, PCV13, PCV15, and PCV20 in children under 5 years old in five Latin American countries.
Key Findings:
PCV20 serotypes caused over 510,000 pneumococcal disease cases and approximately 2,700 deaths annually across the five countries.
The annual economic burden exceeded USD $182 million, with a societal burden exceeding USD $34 million.
Non-invasive diseases like pneumonia and otitis media accounted for most of the burden.
In countries using PCV10, a significant portion of the remaining disease burden was due to serotypes included in PCV13 but not PCV10.
Serotypes unique to PCV20 accounted for a substantial share of the remaining disease burden, particularly in PCV13 NIP countries.
Interpretation:
Despite the effectiveness of PCV10 and PCV13, significant clinical, economic, and societal burdens remain due to serotypes covered by higher-valent vaccines, indicating a need for broader serotype coverage.
Limitations:
The study relies on country-specific epidemiological and cost data, which may vary in accuracy.
Real-world effectiveness data for PCV15 and PCV20 are currently unavailable.
Conclusion:
Broader serotype coverage offered by PCV20 has the potential to further reduce the public health and economic impact of pneumococcal disease in young children across Latin America.
by Sophie Warren, Rafael Bolanos, Lucila Rey-Ares, Juan Manuel Reyes, Jose Luis Huerta, Alana Ranzi, Rodrigo Fernandes Alexandre, Maria Gabriela Abalos, Liping Huang
